{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GLP+-+1&page=2",
    "query": {
      "condition": "GLP - 1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GLP+-+1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T21:13:11.993Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02057172",
      "title": "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "HM11260C",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 254,
      "start_date": "2014-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-08-09",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "CA, California",
      "locations": [
        {
          "city": "CA",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057172"
    },
    {
      "nct_id": "NCT06915090",
      "title": "FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP Support",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "GLP - 1",
        "Diabetes",
        "Obesity and Obesity-related Medical Conditions",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Health Coach/Fitbit",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 15,
      "start_date": "2025-03-18",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06915090"
    },
    {
      "nct_id": "NCT00013910",
      "title": "NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent"
      ],
      "interventions": [
        {
          "name": "NNC 90-1170",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00013910"
    },
    {
      "nct_id": "NCT02975297",
      "title": "Exenatide Once Weekly for Smoking Cessation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "NRT",
          "type": "DRUG"
        },
        {
          "name": "Counseling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-07",
      "completion_date": "2020-01-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02975297"
    },
    {
      "nct_id": "NCT05478707",
      "title": "Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "Dulaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 47,
      "start_date": "2023-10-05",
      "completion_date": "2028-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05478707"
    },
    {
      "nct_id": "NCT07446998",
      "title": "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity & Overweight",
        "Mobility Disability",
        "HOMA-IR"
      ],
      "interventions": [
        {
          "name": "Enobosarm",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide (Wegovy) weekly injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veru Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "65 Years to 100 Years"
      },
      "enrollment_count": 200,
      "start_date": "2026-03-26",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Doral, Florida • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07446998"
    },
    {
      "nct_id": "NCT06500429",
      "title": "A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight and Obesity",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "NG101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide Injectable Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurogastrx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-06-24",
      "completion_date": "2024-09-13",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06500429"
    },
    {
      "nct_id": "NCT07169136",
      "title": "Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycystic Ovarian Syndrome in Adolescent Females",
        "Obesity (Disorder)"
      ],
      "interventions": [
        {
          "name": "GLP-1 Receptor Agonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nemours Children's Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2025-09-11",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169136"
    },
    {
      "nct_id": "NCT06801015",
      "title": "Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-10-01",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06801015"
    },
    {
      "nct_id": "NCT00799435",
      "title": "Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Heart Failure, Diastolic"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2009-07",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2020-09-04",
      "last_synced_at": "2026-06-25T21:13:11.993Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799435"
    }
  ]
}